+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small Molecules Drugs for Inflammatory Bowel Diseases Market - Global Forecast 2026-2032- Product Image
Small Molecules Drugs for Inflammatory Bowel Diseases Market - Global Forecast 2026-2032- Product Image
Sale

Small Molecules Drugs for Inflammatory Bowel Diseases Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083023
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Small Molecules Drugs for Inflammatory Bowel Diseases Market is projected to reach USD 2.36 Billion in 2026. It is expected to continue growing at a CAGR of 5.85%, reaching USD 3.38 Billion by 2032.

Small-Molecule Therapies Are Expanding Options for Inflammatory Bowel Disease

Small-molecule drugs are an important therapeutic class for inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. Unlike biologics, many small molecules are orally administered and can act on intracellular signaling pathways or immune-cell trafficking. Their clinical role is shaped by efficacy, speed of symptom control, durability of remission, safety monitoring, treatment sequencing, and patient preference. The therapeutic objective is increasingly broad: control symptoms, achieve steroid-free remission, support mucosal healing, reduce hospitalizations and surgery, and improve quality of life.

Oral Convenience and Targeted Immunology Are Reshaping IBD Treatment

The IBD treatment landscape is shifting from broad immunosuppression toward more selective pathway modulation and individualized treatment selection. Oral administration may reduce infusion burden and simplify treatment for some patients, while targeted mechanisms create additional options after inadequate response or intolerance to prior therapies. At the same time, regulators and clinicians are emphasizing infection risk, laboratory abnormalities, thrombotic and cardiovascular considerations where relevant, reproductive health, malignancy surveillance, and long-term safety. These changes increase the importance of treat-to-target monitoring, shared decision-making, and evidence from routine clinical practice.

Artificial Intelligence Is Strengthening Discovery, Monitoring, and Treatment Decisions

Artificial intelligence can influence small-molecule IBD development by supporting target identification, compound screening, molecular optimization, and analysis of complex clinical datasets. In care delivery, machine-learning tools may help identify patients at risk of flare, interpret endoscopic or imaging findings, organize longitudinal records, and support adherence interventions. Its cumulative impact will depend on representative data, external validation, transparent performance standards, privacy safeguards, and clinician oversight. AI is therefore best viewed as an augmenting capability rather than a substitute for clinical judgment or prospective evidence.

Regional Differences Reflect Access, Guidelines, and Health-System Capacity

North America generally combines advanced specialty care, broad clinical-trial activity, and established access pathways, although affordability and insurance restrictions can influence treatment sequencing. Europe benefits from structured IBD networks and guideline-driven care, while reimbursement and health-technology-assessment requirements differ across countries. Asia-Pacific includes highly developed markets alongside systems where specialist access and diagnostic capacity remain uneven. Latin America faces variation in reimbursement, referral infrastructure, and medicine availability. The Middle East shows concentrated centers of excellence alongside differing procurement and coverage models. Africa often encounters substantial diagnostic delays, limited specialist capacity, and constrained access to advanced therapies, making scalable monitoring and reliable supply particularly important.

Economic and Political Groupings Highlight Uneven Readiness for Advanced IBD Care

ASEAN markets differ considerably in specialist availability, reimbursement, regulatory maturity, and dependence on imported medicines, creating a need for adaptable access strategies. BRICS countries combine large and diverse patient populations with varied public-private healthcare structures and domestic manufacturing capabilities. European Union systems share regulatory foundations but retain national differences in reimbursement and clinical implementation. G7 members generally have strong research and specialty-care infrastructure, while cost containment and safety evaluation remain central policy concerns. GCC countries often possess substantial healthcare investment and concentrated specialty services, but procurement and population profiles vary. NATO members span highly diverse health systems; cooperation in research, supply resilience, and public-health preparedness can support continuity of care without implying uniform market conditions.

Country Context Determines How Small-Molecule IBD Therapies Are Used

Australia and Canada combine specialist expertise with geographically dispersed populations, making access pathways and remote monitoring relevant. Brazil and Mexico face regional disparities in diagnosis, reimbursement, and specialty care. China and India have substantial clinical and manufacturing capabilities, but access varies by province, state, income, and insurance arrangement. Japan and South Korea have sophisticated healthcare systems with distinct regulatory and prescribing environments. France, Germany, Italy, Spain, and the United Kingdom rely on established specialist networks while applying different reimbursement, assessment, and treatment-guideline processes. Russia’s care environment is shaped by regulatory, procurement, and supply considerations. In the United States, broad specialty infrastructure coexists with significant payer, affordability, and step-therapy variation.

Leaders Should Pair Precision Treatment With Safety, Access, and Evidence Discipline

Industry leaders should prioritize differentiated clinical evidence that measures remission, steroid-free control, endoscopic outcomes, quality of life, and treatment persistence alongside safety. Development programs should incorporate diverse populations, clinically meaningful comparators, patient-reported outcomes, and long-term follow-up. Commercial and access planning should address oral adherence, affordability, reimbursement evidence, diagnostic delays, and clinician education without overstating benefits. Companies and health systems should invest in pharmacovigilance, laboratory-monitoring pathways, interoperable real-world data, and validated AI applications. Regional execution should be tailored to local guidelines, procurement structures, specialist capacity, and regulatory expectations.

Methodology Combines Clinical Evidence With Structured Market-Context Analysis

This executive summary uses a qualitative synthesis of established IBD treatment principles, regulatory and guideline considerations, peer-reviewed clinical evidence, healthcare-system characteristics, and documented technology trends. The analysis compares small-molecule therapies with broader IBD treatment pathways across mechanism, administration, monitoring, safety, patient experience, and implementation. Regional, group, and country observations are framed as contextual differences rather than quantified estimates. No market sizing, share calculations, forecasts, or company-specific claims are included. Conclusions should be validated against current product labels, national guidelines, reimbursement decisions, and newly published clinical data before operational use.

Small Molecules Have a Durable Role in More Individualized IBD Management

Small-molecule drugs can expand therapeutic choice for patients with inflammatory bowel diseases by combining targeted pharmacology with the practical advantages of oral treatment. Their contribution will depend not only on efficacy, but also on durable safety, appropriate patient selection, adherence support, monitoring quality, and equitable access. Regional and country-level differences mean that successful implementation requires locally grounded evidence and delivery models. With disciplined clinical development and responsible use of digital and AI capabilities, small molecules can support a more responsive, treat-to-target approach to IBD care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Indication
7.1. Introduction
7.2. Crohn Disease
7.2.1. Mild
7.2.2. Moderate
7.2.3. Severe
7.3. Ulcerative Colitis
7.3.1. Mild
7.3.2. Moderate
7.3.3. Severe
8. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Mechanism Of Action
8.1. Introduction
8.2. JAK Inhibitors
8.2.1. JAK1 Selective Inhibitors
8.2.2. Pan JAK Inhibitors
8.3. PDE4 Inhibitors
8.4. S1P Receptor Modulators
8.4.1. S1P1 Modulators
8.4.2. S1P1/5 Modulators
9. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Treatment Type
10.1. Introduction
10.2. Induction Therapy
10.3. Maintenance Therapy
11. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Therapy Line
11.1. Introduction
11.2. First Line
11.3. Second Line
11.4. Third Line And Beyond
12. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Development Stage
12.1. Introduction
12.2. Approved
12.3. Clinical Phase II
12.4. Clinical Phase III
13. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. Bristol Myers Squibb Company
17.4. Celgene Corporation
17.5. Eli Lilly and Company
17.6. Galapagos NV
17.7. Gilead Sciences, Inc.
17.8. Gilead Sciences, Inc.
17.9. Johnson & Johnson
17.10. Merck & Co., Inc.
17.11. Mylan N.V.
17.12. Novartis AG
17.13. Pfizer Inc.
17.14. Pfizer Inc.
17.15. Roche Holding AG
17.16. Sandoz International GmbH
17.17. Sun Pharmaceutical Industries Ltd.
17.18. Takeda Pharmaceutical Company Limited
17.19. Teva Pharmaceutical Industries Ltd.
17.20. UCB S.A.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market, Years Considered for the Study
FIGURE 2. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market, Research Design
FIGURE 3. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market, Research Framework
FIGURE 4. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market, Data Triangulation
FIGURE 5. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 9. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 13. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2025 vs 2032 (%)
FIGURE 15. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2025 vs 2032 (%)
FIGURE 17. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Segmentation & Coverage
TABLE 2. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 3. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Crohn Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Crohn Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Crohn Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Mild Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Mild Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Mild Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Mild Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Mild Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Mild Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 29. Global JAK Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global JAK Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global JAK Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global JAK1 Selective Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global JAK1 Selective Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global JAK1 Selective Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Pan JAK Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Pan JAK Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Pan JAK Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global PDE4 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global PDE4 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global PDE4 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global S1P Receptor Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global S1P Receptor Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global S1P Receptor Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global S1P1 Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global S1P1 Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global S1P1 Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global S1P1/5 Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global S1P1/5 Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global S1P1/5 Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 51. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 61. Global Induction Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Induction Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Induction Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Maintenance Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Maintenance Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Maintenance Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 68. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 78. Global Approved Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Approved Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Approved Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Clinical Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Clinical Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Clinical Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Clinical Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Clinical Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Clinical Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 99. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 102. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 103. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 104. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 105. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 106. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 108. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 109. North America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 110. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 113. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 114. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 115. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 116. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 117. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 119. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 120. Latin America Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 121. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 124. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 125. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 126. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 127. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 128. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 130. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 131. Europe Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 132. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 135. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 136. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 137. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 138. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 139. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 141. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 142. Middle East Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 143. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 146. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 147. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 148. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 149. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 150. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 152. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 153. Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 154. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 158. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 159. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 160. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 161. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 162. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 164. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 165. ASEAN Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 166. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 169. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 170. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 171. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 172. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 173. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 175. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 176. GCC Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 177. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 180. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 181. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 182. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 183. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 184. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 186. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 187. European Union Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 188. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 190. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 191. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 192. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 193. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 194. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 195. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 197. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 198. BRICS Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 199. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 202. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 203. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 204. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 205. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 206. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 208. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 209. G7 Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 210. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 211. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 213. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 214. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 215. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 216. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 217. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 219. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 220. NATO Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 221. Global Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 222. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 223. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 225. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 226. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 227. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 228. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 229. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 231. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 232. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 233. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 234. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 235. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 236. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 237. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 238. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 239. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 240. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 242. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 243. Canada Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 244. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 245. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 246. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 247. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 248. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 249. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 250. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 251. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 253. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 254. Mexico Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 255. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 256. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 257. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 258. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 259. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 260. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 261. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 262. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 264. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 265. Brazil Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 266. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 267. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 269. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 270. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 271. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhibitors, 2017-2032 (USD Million)
TABLE 272. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by S1P Receptor Modulators, 2017-2032 (USD Million)
TABLE 273. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 275. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 276. United Kingdom Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 277. Germany Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, 2017-2032 (USD Million)
TABLE 278. Germany Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Indication, 2017-2032 (USD Million)
TABLE 279. Germany Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 280. Germany Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 281. Germany Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 282. Germany Small Molecules Drugs for Inflammatory Bowel Diseases Market Size, by JAK Inhi

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Related Topics

Related Reports

Inflammatory Bowel Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033

  • Report
  • 183 Pages
  • Global
From
Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 504 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Report by Drug Class, Disease Indication, Distribution Channel, Country and Company Analysis 2026-2034 - Product Image

Inflammatory Bowel Disease Treatment Market Report by Drug Class, Disease Indication, Distribution Channel, Country and Company Analysis 2026-2034

  • Report
  • 200 Pages
  • Global
From
Protein Hydrolysates for Inflammatory Bowel Disease Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Protein Hydrolysates for Inflammatory Bowel Disease Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 210 Pages
  • Global
From
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 295 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.